Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors

Journal of Clinical Investigation

Volumn 125, Issue 12, 2015, Pages 4666-4680

  Henry, Curtis J ^a,b   Casás Selves, Matias ^a   Kim, Jihye ^a   Zaberezhnyy, Vadym ^a   Aghili, Leila ^a   Daniel, Ashley E ^a   Jimenez, Linda ^a   Azam, Tania ^a   McNamee, Eoin N ^a   Clambey, Eric T ^a   Klawitter, Jelena ^a   Serkova, Natalie J ^a   Tan, Aik Choon ^a   Dinarello, Charles A ^a,c   DeGregori, James ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INTERLEUKIN 1BETA; INTERLEUKIN 37; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; NEUTRALIZING ANTIBODY; STAT5A PROTEIN; STAT5B PROTEIN; TUMOR NECROSIS FACTOR ALPHA; BCR ABL PROTEIN; MYC PROTEIN; MYC PROTEIN, MOUSE;

AGING; ANIMAL EXPERIMENT; ARTICLE; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL POPULATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC STEM CELL; INFLAMMATION; LEUKEMOGENESIS; LYMPHOPOIESIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ONCOGENE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PURINE SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW; CELL TRANSFORMATION; GENETICS; METABOLISM; PATHOLOGY; STEM CELL NICHE; TRANSGENIC MOUSE;

AGING; ANIMALS; BONE MARROW; CELL TRANSFORMATION, NEOPLASTIC; FUSION PROTEINS, BCR-ABL; INFLAMMATION; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PRECURSOR CELLS, B-LYMPHOID; PROTO-ONCOGENE PROTEINS C-MYC; STEM CELL NICHE;

EID: 84948798306     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83024     Document Type: Article

References (84)

1. DePinho RA. The age of cancer. Nature. 2000;408(6809):248-254.
2. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-1217.
3. Chan GK, Duque G. Age-related bone loss: old bone, new facts. Gerontology. 2002;48(2):62-71.
4. Dykstra B, Olthof S, Schreuder J, Ritsema M, de Haan G. Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. J Exp Med. 2011;208(13):2691-2703.
5. Rossi DJ, Bryder D, Weissman IL. Hematopoietic stem cell aging: mechanism and consequence. Exp Gerontol. 2007;42(5):385-390.
6. Pang WW, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA. 2011;108(50):20012-20017.
7. Rossi DJ, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci USA. 2005;102(26):9194-9199.
8. Geiger H, de Haan G, Florian MC. The ageing haematopoietic stem cell compartment. Nat Rev Immunol. 2013;13(5):376-389.
9. Snoeck HW. Aging of the hematopoietic system. Curr Opin Hematol. 2013;20(4):355-361.
10. Beerman I, et al. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci USA. 2010;107(12) 5465-5470.
11. Allman D, Miller JP. The aging of early B-cell precursors. Immunol Rev. 2005;205:18-29.
12. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5(2):133-139.
13. Guerrettaz LM, Johnson SA, Cambier JC. Acquired hematopoietic stem cell defects determine B-cell repertoire changes associated with aging. Proc Natl Acad Sci USA. 2008;105(33):11898-11902.
14. Riley RL. Impaired B lymphopoiesis in old age: a role for inflammatory B cells? Immunol Res. 2013;57(1-3):361-369.
15. Labrie JE 3rd, Sah AP, Allman DM, Cancro MP, Gerstein RM. Bone marrow microenvironmental changes underlie reduced RAG-mediated recombination and B cell generation in aged mice. J Exp Med. 2004;200(4):411-423.
16. Henry CJ, Marusyk A, Zaberezhnyy V, Adane B, DeGregori J. Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis. Proc Natl Acad Sci USA. 2010;107(50):21713-21718.
17. Pronk CJ, Veiby OP, Bryder D, Jacobsen SE. Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors. J Exp Med. 2011;208(8):1563-1570.
18. Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-p1. Cell Stem Cell. 2010;6(3):265-278.
19. Essers MA, et al. IFNa activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904-908.
20. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN-y in response to chronic infection. Nature. 2010;465(7299):793-797.
21. Pietras EM, et al. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med. 2014;211(2):245-262.
22. Nagai Y, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity. 2006;24(6):801-812.
23. Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med. 2005;201(11):1771-1780.
24. Ueda Y, Yang K, Foster SJ, Kondo M, Kelsoe G. Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression. J Exp Med. 2004;199(1):47-58.
25. Ratliff M, Alter S, Frasca D, Blomberg BB, Riley RL. In senescence, age-associated B cells secrete TNFα and inhibit survival of B-cell precursors. Aging Cell. 2013;12(2):303-311.
26. Goto M. Inflammaging (inflammation + aging): a driving force for human aging based on an evo-lutionarily antagonistic pleiotropy theory? Biosci Trends. 2008;2(6):218-230.
27. Okin D, Medzhitov R. Evolution of inflammatory diseases. Curr Biol. 2012;22(17):R733-R740.
28. Michaud M, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14(12):877-882.
29. Giunta B, et al. Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation. 2008;5:51.
30. Lencel P, Magne D. Inflammaging: the driving force in osteoporosis? Med Hypotheses. 2011;76(3):317-321.
31. Franceschi C, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-254.
32. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130(2):223-233.
33. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med. 2009;361(15):1475-1485.
34. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
35. Rozhok AI, Salstrom JL, DeGregori J. Stochastic modeling indicates that aging and somatic evolution in the hematopoetic system are driven by non-cell-autonomous processes. Aging. 2014;6(12):1033-1048.
36. Vijg J, Busuttil RA, Bahar R, Dolle ME. Aging and genome maintenance. Ann N Y Acad Sci. 2005;1055:35-47.
37. Miller JP, Allman D. The decline in B lymphopoiesis in aged mice reflects loss of very early B-lineage precursors. J Immunol. 2003;171(5):2326-2330.
38. Dias S, Silva H Jr, Cumano A, Vieira P. Interleu-kin-7 is necessary to maintain the B cell potential in common lymphoid progenitors. J Exp Med. 2005;201(6):971-979.
39. Flach J, et al. Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. Nature. 2014;512(7513):198-202.
40. Miller JP, Allman D. Linking age-related defects in B lymphopoiesis to the aging of hematopoietic stem cells. Semin Immunol. 2005;17(5):321-329.
41. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172-183.
42. Mirantes C, Passegué E, Pietras EM. Pro-inflammatory cytokines: emerging players regulating HSC function in normal and diseased hemato-poiesis. Exp Cell Res. 2014;329(2):248-254.
43. Casalino-Matsuda SM, Monzon ME, Day AJ, Forteza RM. Hyaluronan fragments/CD44 mediate oxidative stress-induced MUC5B up-regu-lation in airway epithelium. Am J Respir Cell Mol Biol. 2009;40(3):277-285.
44. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999;10(3):387-398.
45. McNamee EN, et al. Chemokine receptor CCR7 regulates the intestinal TH1/TH17/Treg balance during Crohn's-like murine ileitis. J Leukoc Biol. 2015;97(6):1011-1022.
46. Lewis EC, et al. α1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci USA. 2008;105(42):16236-16241.
47. Pott GB, Chan ED, Dinarello CA, Shapiro L. α1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol. 2009;85(5):886-895.
48. Lewis EC. Expanding the clinical indications for α(1)-antitrypsin therapy. Mol Med. 2012;18:957-970.
49. Dinarello CA, Kim S, Bufler P. IL-37: the IL-1 family member you never expected. Eur J Immunol. In press.
50. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39(6):1003-1018.
51. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11(11):1014-1022.
52. Oh J, Lee YD, Wagers AJ. Stem cell aging: mechanisms, regulators and therapeutic opportunities. Nat Med. 2014;20(8):870-880.
53. Conboy MJ, Conboy IM, Rando TA. Hetero chronic parabiosis: historical perspective and methodological considerations for studies of aging and longevity. Aging Cell. 2013;12(3):525-530.
54. Cheleuitte D, Mizuno S, Glowacki J. In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J Clin Endo-crinol Metab. 1998;83(6):2043-2051.
55. Welner RS, et al. Treatment of chronic myeloge-nous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell. 2015;27(5):671-681.
56. Reynaud D, et al. IL-6 controls leukemic mul-tipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell. 2011;20(5):661-673.
57. Kleppe M, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5(3):316-331.
58. Min H, Montecino-Rodriguez E, Dorshkind K. Effects of aging on early B-and T-cell development. Immunol Rev. 2005;205:7-17.
59. Geiger H, Zheng Y. Cdc42 and aging of hematopoietic stem cells. Curr Opin Hematol. 2013;20(4):295-300.
60. Chambers SM, Shaw CA, Gatza C, Fisk CJ, Done-hower LA, Goodell MA. Aging hematopoietic stem cells decline in function and exhibit epige-netic dysregulation. PLoS Biol. 2007;5(8):e201.
61. Cullen SM, Mayle A, Rossi L, Goodell MA. Hematopoietic stem cell development: an epige-netic journey. Curr Top Dev Biol. 2014;107:39-75.
62. Walter D, et al. Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. Nature. 2015;520(7548):549-552.
63. Frith CH, Ward JM, Chandra M. The morphology, immunohistochemistry, and incidence of hematopoietic neoplasms in mice and rats. Toxicol Pathol. 1993;21(2):206-218.
64. Henry CJ, Marusyk A, DeGregori J. Aging-associated changes in hematopoiesis and leu-kemogenesis: what's the connection? Aging. 2011;3(6):643-656.
65. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6(3):193-203.
66. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
67. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175-1183.
68. Jaiswal S, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498.
69. Genovese G, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
70. Xie M, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472-1478.
71. Jacobs KB, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44(6):651-658.
72. Laurie CC, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44(6):642-650.
73. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythe-mia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119(14):3219-3225.
74. Kralovics R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790.
75. Vas V, Wandhoff C, Dorr K, Niebel A, Geiger H. Contribution of an aged microenvironment to aging-associated myeloproliferative disease. PLoS One. 2012;7(2):e31523.
76. Vas V, Senger K, Dorr K, Niebel A, Geiger H. Aging of the microenvironment influences clonality in hematopoiesis. PLoS One. 2012;7(8):e42080.
77. Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf AR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29(21):2897-2903.
78. Cuzick J, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann O ncol. 2015;26(1):47-57.
79. Streicher SA, Yu H, Lu L, Kidd MS, Risch HA. Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1254-1263.
80. Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer. 2013;132(5):1146-1155.
81. Navarrete-Reyes AP, Montana-Alvarez M. [Inflammaging. Aging inflammatory origin]. Rev Invest Clin. 2009;61(4):327-336.
82. Franceschi C, et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev. 2005;126(2):351-361.
83. DeGregori J. Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age? Oncogene. 2013;32(15):1869-1875.
84. Bilousova G, Marusyk A, Porter CC, Cardiff RD, DeGregori J. Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol. 2005;3(12):e401.